Teva Pharmaceutical Industries (TEVA) Gains from Investment Securities (2009 - 2026)

Teva Pharmaceutical Industries has disclosed Gains from Investment Securities across 18 years of filings, most recently posting -$1.0 million for Q1 2026.

• Quarterly Gains from Investment Securities changed N/A year-over-year to -$1.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$6.0 million (down 200.0% YoY) and the FY2025 annual result came in at -$5.0 million, down 150.0% from the prior year.
• Gains from Investment Securities improved to -$1.0 million in Q1 2026, from -$2.0 million in the prior quarter.
• Over five years, Gains from Investment Securities peaked at $4.0 million in Q4 2022 and troughed at -$3.0 million in Q3 2022.
• A 5-year average of $0.0 and a median of $0.0 in 2022 frame the typical range for Gains from Investment Securities.
• Biggest YoY gain for Gains from Investment Securities was 300.0% in 2023; the steepest drop was 125.0% in 2023.
• Tracing TEVA's Gains from Investment Securities over 5 years: stood at $4.0 million in 2022, then sank by 125.0% to -$1.0 million in 2023, then tumbled by 100.0% to -$2.0 million in 2024, then changed by 0.0% to -$2.0 million in 2025, then soared by 50.0% to -$1.0 million in 2026.
• Business Quant data shows TEVA's Gains from Investment Securities at -$1.0 million in Q1 2026, -$2.0 million in Q3 2025, and -$3.0 million in Q2 2025.